Reviewer's report

Title: Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia

Version: 2
Date: 25 December 2013

Reviewer: Javier Diez-Domingo

Reviewer's report:

This is a cost effectiveness analysis of the use of pneumococcal vaccines in adults in Colombia.

In general the paper follows the CHEERS checklist and is clearly written.

Major Compulsory Revision:
Impact of Prevenar 13 on adult pneumonia: There is no data on the effectiveness of the vaccine to prevent pneumonia in adults. While in America the vaccine is licensed with the indication of prevention of IPD and Pneumonia, in Europe is only indicated for the prevention of IPD, therefore the sensitivity analysis should include an effectiveness to prevent pneumonia ranging from 0 to the estimated in the paper (24% for inpatient or 5.6% for outpatient). That will allow to better assess the cost effectiveness once the clinical trial CAPITA is presented (to estimate the prevention of Pneumonia in adults).

It is important that the authors state whether the Markov model was developed by themselves or they used other's model, especially if it was Pfizer's.

Minor essential revisions:
In the description of demographic and epidemiological parameters, when describing medium risk subjects, please delete 'personas'

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have been principal investigator and national coordinator of clinical trials assessing immunogenicity of prevenar 13 in infants.
My institution (CSISP) received a grant in 2010 from Pfizer for pneumococcal epidemiological studies.
I participated in advisory boards (Pfizer) for Prevenar 13 in children.